Danaher Co. (NYSE:DHR) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC reduced its position in Danaher Co. (NYSE:DHR) by 5.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 303,432 shares of the conglomerate’s stock after selling 18,222 shares during the quarter. AQR Capital Management LLC’s holdings in Danaher were worth $75,813,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Tsfg LLC boosted its holdings in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the second quarter valued at approximately $25,000. nVerses Capital LLC bought a new position in shares of Danaher during the second quarter valued at approximately $25,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the 1st quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. bought a new stake in shares of Danaher in the 4th quarter worth approximately $42,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Down 0.5 %

Shares of DHR stock opened at $275.47 on Friday. The stock has a 50-day simple moving average of $270.23 and a 200 day simple moving average of $257.84. The stock has a market capitalization of $204.04 billion, a P/E ratio of 46.69, a P/E/G ratio of 4.55 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the firm posted $2.05 EPS. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. On average, sell-side analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. Danaher’s dividend payout ratio is currently 18.31%.

Insider Activity

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,659 shares of company stock worth $11,042,433. Insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of several analyst reports. Wells Fargo & Company started coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. TD Cowen lifted their price objective on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Jefferies Financial Group started coverage on shares of Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Finally, The Goldman Sachs Group increased their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.